Teva Pharmaceutical Industries Limited (TEVA) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic · NYSE
Teva Pharmaceutical Industries Limited (TEVA) posted $17.26B in revenue for fiscal 2025 (up 4.3% year over year), at a 8.2% net margin, and has compounded revenue about 0.7%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited has grown revenue from $21.90B to $17.26B over the last 10 fiscal years, compounding about 0.7% a year. The most recent year was up 4.3%, so growth is actually accelerating.
Net margin sits at 8.2%, up 18.1 points year over year on a 51.8% gross margin. It carries about $16.81B of total debt.
At today's valuation the market is pricing in roughly 15.3% annual free-cash-flow growth — versus the 12.5% it actually delivered over the last five years, broadly in line with what it has delivered. The one thing worth a second look in the filings is receivables growing faster than sales.
Synthesised from Teva Pharmaceutical Industries Limited's SEC filings — descriptive, not advice. Ask the analyst your own question →
Teva Pharmaceutical Industries Limited revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.90B | $21.85B | $18.27B | $16.89B | $16.66B | $15.88B | $14.93B | $15.85B | $16.54B | $17.26B |
| Gross profit | $11.65B | $10.62B | $8.30B | $7.54B | $7.73B | $7.59B | $6.97B | $7.64B | $8.06B | $8.94B |
| Net income | $329.00M | $-16.27B | $-2.15B | $-999.00M | $-3.99B | $417.00M | $-2.45B | $-559.00M | $-1.64B | $1.41B |
| Net margin | 1.5% | -74.4% | -11.8% | -5.9% | -24.0% | 2.6% | -16.4% | -3.5% | -9.9% | 8.2% |
Source: Teva Pharmaceutical Industries Limited SEC filings (10-K). 11 years of history available in the interactive view.
Teva Pharmaceutical Industries Limited: 2 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Receivables growing faster than salesAccounts receivable rose 21.2% while revenue rose 4.3% in the latest year — a gap that can signal looser credit terms or pulled-forward sales. Worth checking days-sales-outstanding.
- Heavy debt loadTotal debt of $18626M is 11.3× last year's operating cash flow — it would take years of cash flow to clear.
What growth is priced into TEVA stock?
At today's market cap of $40.11B, Teva Pharmaceutical Industries Limited is priced for free-cash-flow growth of about 15.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.15B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 12.5%/yr over the last five fiscal years and revenue 0.7%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 11 years of Teva Pharmaceutical Industries Limited financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TEVA in your portfolio →
Teva Pharmaceutical Industries Limited financial history by metric
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Teva Pharmaceutical Industries Limited — frequently asked questions
What is Teva Pharmaceutical Industries Limited's revenue?
Teva Pharmaceutical Industries Limited (TEVA) reported revenue of $17.26B for fiscal year 2025, up 4.3% from the prior year, according to its SEC filings.
Is Teva Pharmaceutical Industries Limited profitable?
Yes. TEVA earned net income of $1.41B in fiscal 2025, a net margin of 8.2%.
What is TEVA's P/E ratio?
Teva Pharmaceutical Industries Limited trades at a price-to-earnings ratio of about 25.7 based on the latest data in our nightly-refreshed cache.
How fast is Teva Pharmaceutical Industries Limited growing?
TEVA's revenue grew at roughly 0.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Teva Pharmaceutical Industries Limited have?
As of fiscal year 2025, TEVA carried roughly $16.81B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Teva Pharmaceutical Industries Limited's gross margin?
TEVA's gross margin was 51.8% in fiscal 2025 — gross profit of $8.94B on revenue of $17.26B.
What is Teva Pharmaceutical Industries Limited's market cap?
Teva Pharmaceutical Industries Limited (TEVA) has a market capitalization of about $40.11B, based on the latest data in our nightly-refreshed cache.
When does Teva Pharmaceutical Industries Limited's fiscal year end?
TEVA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into TEVA stock?
At today's market cap of $40.11B, Teva Pharmaceutical Industries Limited is priced for free-cash-flow growth of about 15.3% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $1.15B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 12.5%/yr over the last five fiscal years and revenue 0.7%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Teva Pharmaceutical Industries Limited's official SEC filings (10-K and 10-Q), covering 11 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.